Gene

CD44

CD44 molecule (IN blood group)

Explore in graph →CI-GENE-00040510HGNC:1681 ENSG00000026508 NCBI 960 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (17)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–17 of 17 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD44 CD44s1
(prognostic)	Malignant Gastric Neoplasm	Prognostic	B	Supports Poor Outcome	4	submitted	EID9426 In a multivariate analysis from a clinical study including 123 resected primary gastric cancer, CD44s expression at invasive tumor front correlates with a decrease in survival (p< 0.0001). Moreover CD…

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Acute Myeloid Leukemia TARGET-AML	Acute Myeloid LeukemiaCURATED_BROADER

Literature

Linked publications (2)

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
· Cancer Sci · 2015 · PMID 26250934 · validated civic_curation pubmed
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
· Clin Cancer Res · 2015 · PMID 25762343 · validated civic_curation pubmed

CD44 CD44s Expression1
RG7356	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID825 CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, … (full text at CIViC) PMID 25762343 · Birzele et al., 2015 · Open in CIViC	civic

CD44 CD44s Expression1

RG7356

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID825

CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, … (full text at CIViC)

PMID 25762343 · Birzele et al., 2015 · Open in CIViC

civic

CD44 CD44v68
(prognostic)	Hepatocellular Carcinoma	Prognostic	B	Supports Poor Outcome	5	submitted	EID9407 In a meta-analysis including nine trials with a total of 942 patients, high CD44v6 expression is significantly associated with a decrease in survival outcome (HR 2.13, 95% CI: 1.58 to 2.88). PMID 25887688 · Fu et al., 2015 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Prognostic	B	Supports Poor Outcome	5	submitted	EID9408 In a meta-analysis including 4 studies with a total of 629 patients, CD44v6 expression is significantly correlated with a decrease in OS (HR 1.76, 95% IC: 1.30 to 2.39). One study that affects heterog… (full text at CIViC) PMID 27977599 · Lu et al., 2016 · Open in CIViC	civic
〃	Melanoma	Prognostic	B	Supports Poor Outcome	4	submitted	EID9406 Among 51 patients, patients expressing CD44v6 in primary melanoma were classified in the "high-risk for MBM" group with a sensitivity of 71.4% and a specificity of 60.9% (AUC = 0.68) Moreover, among 5… (full text at CIViC) PMID 25169209 · Marzese et al., 2015 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID9427 In a clinical study including 59 stage III-IV ovarian cancer patients with peritoneal disseminated tumors, Kaplan-Meier analysis showed a significant association between CD44v6 high expression and wor… (full text at CIViC) PMID 26250934 · Tjhay et al., 2015 · Open in CIViC	civic
Cisplatin	Malignant Cervical Neoplasm	Predictive	B	Supports Resistance	4	submitted	EID9481 In a clinical trial including 21 patients, CD44v6 expression (prior to and after to NAC) is a predictive factor of response to NAC by multivariate analysis (p = 0.0099 and p = 0.0470). Moreover, CD44v… (full text at CIViC) PMID 11136572 · Costa et al., 2001 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	D	Supports Resistance	4	submitted	EID9438 In an in vitro study, CD44v6 knockdown or deletion of exon 11 (v6 specific) had an decrease in cell survival compared to mock cells treated with scramble siRNA when treated with cisplatin or 5-fluorou… (full text at CIViC) PMID 32842638 · Lobo et al., 2020 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID9429 In an in vitro chemosensitivtiy assay, FACS-sorted CD44v6-positive cells show a significantly higher viability compared to CD44v6-negative cells when treated with 10nM of paclitaxel or 9 uM of cisplat… (full text at CIViC) PMID 26250934 · Tjhay et al., 2015 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID9430 In an in vitro study, CD44v6 expressing cell lines survive better to 10 uM of cisplatin compared to mock cells, whereas no differential response was observed in response to 5-fluorouracil (p< 0.05). M… (full text at CIViC) PMID 32252293 · Pereira et al., 2020 · Open in CIViC	civic

CD44 CD44v68

(prognostic)

Hepatocellular Carcinoma

Prognostic

Supports Poor Outcome

submitted

EID9407

In a meta-analysis including nine trials with a total of 942 patients, high CD44v6 expression is significantly associated with a decrease in survival outcome (HR 2.13, 95% CI: 1.58 to 2.88).

PMID 25887688 · Fu et al., 2015 · Open in CIViC

civic

〃

Malignant Gastric Neoplasm

Prognostic

Supports Poor Outcome

submitted

EID9408

In a meta-analysis including 4 studies with a total of 629 patients, CD44v6 expression is significantly correlated with a decrease in OS (HR 1.76, 95% IC: 1.30 to 2.39). One study that affects heterog… (full text at CIViC)

PMID 27977599 · Lu et al., 2016 · Open in CIViC

civic

〃

Melanoma

Prognostic

Supports Poor Outcome

submitted

EID9406

Among 51 patients, patients expressing CD44v6 in primary melanoma were classified in the "high-risk for MBM" group with a sensitivity of 71.4% and a specificity of 60.9% (AUC = 0.68) Moreover, among 5… (full text at CIViC)

PMID 25169209 · Marzese et al., 2015 · Open in CIViC

civic

〃

Malignant Ovarian Neoplasm

Prognostic

Supports Poor Outcome

accepted

EID9427

In a clinical study including 59 stage III-IV ovarian cancer patients with peritoneal disseminated tumors, Kaplan-Meier analysis showed a significant association between CD44v6 high expression and wor… (full text at CIViC)

PMID 26250934 · Tjhay et al., 2015 · Open in CIViC

civic

Cisplatin

Malignant Cervical Neoplasm

Predictive

Supports Resistance

submitted

EID9481

In a clinical trial including 21 patients, CD44v6 expression (prior to and after to NAC) is a predictive factor of response to NAC by multivariate analysis (p = 0.0099 and p = 0.0470). Moreover, CD44v… (full text at CIViC)

PMID 11136572 · Costa et al., 2001 · Open in CIViC

civic

〃

Malignant Gastric Neoplasm

Predictive

Supports Resistance

submitted

EID9438

In an in vitro study, CD44v6 knockdown or deletion of exon 11 (v6 specific) had an decrease in cell survival compared to mock cells treated with scramble siRNA when treated with cisplatin or 5-fluorou… (full text at CIViC)

PMID 32842638 · Lobo et al., 2020 · Open in CIViC

civic

〃

Malignant Ovarian Neoplasm

Predictive

Supports Resistance

submitted

EID9429

In an in vitro chemosensitivtiy assay, FACS-sorted CD44v6-positive cells show a significantly higher viability compared to CD44v6-negative cells when treated with 10nM of paclitaxel or 9 uM of cisplat… (full text at CIViC)

PMID 26250934 · Tjhay et al., 2015 · Open in CIViC

civic

〃

Malignant Gastric Neoplasm

Predictive

Supports Resistance

submitted

EID9430

In an in vitro study, CD44v6 expressing cell lines survive better to 10 uM of cisplatin compared to mock cells, whereas no differential response was observed in response to 5-fluorouracil (p< 0.05). M… (full text at CIViC)

PMID 32252293 · Pereira et al., 2020 · Open in CIViC

civic

CD44 CD44v10 + CD44 CD44v61
(prognostic)	Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	3	submitted	EID9435 In a clinical study including 82 patients, a Kaplan-Meier analysis showed a significant association between CD44v6 expression (high and low) and worse disease-free survival (p = 0.03). Another Kaplan-… (full text at CIViC) PMID 19507218 · Wang et al., 2009 · Open in CIViC	civic

CD44 CD44v10 + CD44 CD44v61

(prognostic)

Squamous Cell Carcinoma

Prognostic

Supports Poor Outcome

submitted

EID9435

In a clinical study including 82 patients, a Kaplan-Meier analysis showed a significant association between CD44v6 expression (high and low) and worse disease-free survival (p = 0.03). Another Kaplan-… (full text at CIViC)

PMID 19507218 · Wang et al., 2009 · Open in CIViC

civic

CD44 CD44v5 + CD44 CD44v61
(prognostic)	Malignant Colorectal NeoplasmCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	submitted	EID9432 In a clinical study including 105 patients with resectable colorectal carcinomas, a Kaplan-Meier analysis showed a significant association between CD44v5 high expression and worse free time of disease… (full text at CIViC) PMID 15300427 · Vizoso et al., 2004 · Open in CIViC	civic

CD44 CD44v5 + CD44 CD44v61

(prognostic)

Malignant Colorectal NeoplasmCURATED_BROADER

Prognostic

Supports Poor Outcome

submitted

EID9432

In a clinical study including 105 patients with resectable colorectal carcinomas, a Kaplan-Meier analysis showed a significant association between CD44v5 high expression and worse free time of disease… (full text at CIViC)

PMID 15300427 · Vizoso et al., 2004 · Open in CIViC

civic

CD44 CD44v6+/CD44s-1
(prognostic)	Pancreatic Carcinoma	Prognostic	B	Supports Poor Outcome	4	submitted	EID9433 In a multivariate analysis from a clinical trial of 101 patients, CD44v6 expression combined with CD44s non-expression is significantly correlated with a reduced survival (p= 0.003). PMID 24708709 · Li et al., 2014 · Open in CIViC	civic

CD44 CD44v6+/CD44s-1

(prognostic)

Pancreatic Carcinoma

Prognostic

Supports Poor Outcome

submitted

EID9433

In a multivariate analysis from a clinical trial of 101 patients, CD44v6 expression combined with CD44s non-expression is significantly correlated with a reduced survival (p= 0.003).

PMID 24708709 · Li et al., 2014 · Open in CIViC

civic

CD44 CD44v8-v101
Docetaxel	Malignant Prostate Neoplasm	Predictive	D	Supports Reduced Sensitivity	3	submitted	EID9434 In an in vitro study using docetaxel-resistant PC-3R cells, knockdown with CD44v8-10 siRNAs increased sensitivity to docetaxel (p < 0.05) compared to negative control. PMID 32642575 · Kato et al., 2020 · Open in CIViC	civic

CD44 CD44v8-v101

Docetaxel

Malignant Prostate Neoplasm

Predictive

Supports Reduced Sensitivity

submitted

EID9434

In an in vitro study using docetaxel-resistant PC-3R cells, knockdown with CD44v8-10 siRNAs increased sensitivity to docetaxel (p < 0.05) compared to negative control.

PMID 32642575 · Kato et al., 2020 · Open in CIViC

civic

CD44 CD44v3-v10 + CD44 CD44v8-v101
RG7356	Malignant NeoplasmALIAS	Predictive	B	Supports Resistance	4	submitted	EID9395 In RG7356 xenograft models, cell lines expressing predominantly a mixture of CD44v8-v10 and CD44v3-v10 show no response to treatment with RG7356 measured as a percentage of tumor growth inhibition. In… (full text at CIViC) PMID 25762343 · Birzele et al., 2015 · Open in CIViC	civic

CD44 CD44v3-v10 + CD44 CD44v8-v101

RG7356

Malignant NeoplasmALIAS

Predictive

Supports Resistance

submitted

EID9395

In RG7356 xenograft models, cell lines expressing predominantly a mixture of CD44v8-v10 and CD44v3-v10 show no response to treatment with RG7356 measured as a percentage of tumor growth inhibition. In… (full text at CIViC)

PMID 25762343 · Birzele et al., 2015 · Open in CIViC

civic

CD44 CD44v92
(prognostic)	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	4	submitted	EID9396 In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC) PMID 25751671 · Aso et al., 2015 · Open in CIViC	civic
〃	Bladder Urothelial Carcinoma	Prognostic	B	Supports Poor Outcome	4	submitted	EID9397 After second line treatment with cisplatin, 64 patients with positive immunohistochemical staining of CD44v9 show a significant decrease of cancer specific survival rate (p = 0.008). In multivariate a… (full text at CIViC) PMID 29385995 · Hagiwara et al., 2018 · Open in CIViC	civic

CD44 CD44v92

(prognostic)

Head and Neck Squamous Cell Carcinoma

Prognostic

Supports Poor Outcome

submitted

EID9396

In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC)

PMID 25751671 · Aso et al., 2015 · Open in CIViC

civic

〃

Bladder Urothelial Carcinoma

Prognostic

Supports Poor Outcome

submitted

EID9397

After second line treatment with cisplatin, 64 patients with positive immunohistochemical staining of CD44v9 show a significant decrease of cancer specific survival rate (p = 0.008). In multivariate a… (full text at CIViC)

PMID 29385995 · Hagiwara et al., 2018 · Open in CIViC

civic